Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 1.00 |
| ▸ | CCND1 | P24385 | 20/20 | 1.00 |
| ▸ | CCND2 | P30279 | 20/20 | 1.00 |
| ▸ | CCND3 | P30281 | 20/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.77 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.77 |
| ▸ | CDK1 | P06493 | 2/20 | 0.77 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.77 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.77 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.77 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.77 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.77 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.77 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.77 |
| ▸ | CDK2 | P24941 | 2/20 | 0.77 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.77 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.77 |
| ▸ | SRC | P12931 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6808742 | 0.90 | CDK4 (0.82) | CDK4CCND1CCND2CCND3CCNB2 | |
| SCHEMBL6803927 | 0.89 | CDK4 (0.81) | CDK4CCND1CCND2CCND3CCNB2 | |
| SCHEMBL6804579 | 0.88 | CDK4 (0.79) | CDK4CCND1CCND2CCND3CCNB2 | |
| SCHEMBL5265124 | 0.88 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CCNB2 | |
| SCHEMBL5263860 | 0.87 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CCNB2 | |
| SCHEMBL6808284 | 0.87 | CDK4 (0.77) | CDK4CCND1CCND2CCND3CCNB2 | |
| SCHEMBL4352697 | 0.86 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CCNB2 | |
| SCHEMBL5264944 | 0.86 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CCNB2 | |
| SCHEMBL6812127 | 0.85 | CDK4 (0.74) | CDK4CCND1CCND2CCND3CCNB2 | |
| SCHEMBL5265563 | 0.85 | CDK4 (0.81) | CDK4CCND1CCND2CCND3CCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1806348-A2 | Pyrido (2,3-D)Pyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-07-11 | — | — | EP | claimed |
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | BOOTH RICHARD JOHN (US) | 2004-11-11 | — | — | US | claimed |
| US-6498163-B1 | POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES AND GROWTH FACTOR MEDIATED KINASES; CANCER, RESTENOSIS, ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2002-12-24 | — | — | US | claimed |
| EP-1255755-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | claimed |
| WO-2001055148-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | claimed |
| EP-0964864-A2 | PYRIDO 2,3-D] PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-22 | — | — | EP | claimed |
| WO-1998033798-A2 | PYRIDO[2,3-D]PYRIMIDINES AND 4-AMINO-PYRIMIDINES AS INHIBITORS OF CELL PROLIFERATION | WARNER LAMBERT COMPANY (US) | 1998-08-06 | — | — | WO | claimed |
| EP-1806348-A2 | Pyrido (2,3-D)Pyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | BOOTH RICHARD JOHN (US) | 2004-11-11 | — | — | US | disclosed |
| US-6498163-B1 | POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES AND GROWTH FACTOR MEDIATED KINASES; CANCER, RESTENOSIS, ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2002-12-24 | — | — | US | disclosed |
| EP-1255755-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001055148-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| EP-0964864-A2 | PYRIDO 2,3-D] PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-22 | — | — | EP | disclosed |
| WO-1998033798-A2 | PYRIDO[2,3-D]PYRIMIDINES AND 4-AMINO-PYRIMIDINES AS INHIBITORS OF CELL PROLIFERATION | WARNER LAMBERT COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | CDK4, CDKL1, CCNT1 | CDK4 1/4885CCND1 23/4885CCND2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.